Breaking News

Risk-benefit assessment of adalimumab, etanercept and infliximab in psoriasis patients

Risk-benefit assessment of adalimumab, etanercept and infliximab in psoriasis patients

 
 

A risk-benefit analysis was calculated for adalimumab, etanercept and infliximab in psoriasis patients. The number needed to treat (NNT) to give a 75% or 90% improvement in the Psoriasis Area and Severity Index (PASI75 or PASI90) in one additional patient and number needed to harm (NNH) to observe an additional adverse event relative to placebo were derived from placebo-controlled trials of the three agents. By pooling long-term safety results, the number of patient-years (NPYs) for an extra case of serious infection, malignancy (nonmelanoma skin cancer [NMSC], lymphoma calculated separately), tuberculosis, congestive heart failure, demyelinating disease/peripheral neuropathy, lupus/lupus-like syndrome were calculated. The NNT PASI75 results were 1.4, 1.6, 2.3 and 3.2 for infliximab (5 ...

 
to Continue Reading, Login Now
 

Please Login

 
 
  
 
 
If you are a registered user but you have forgotten your password, please click here
 
If you are not a registered user, please register here

return to breaking news list